Regeneron halts Phase 1/2a uveitis trial of anti-CD3 antibody after safety event

Regeneron announced it is voluntarily ending the Phase 1/2a TITAN study of its anti‑CD3 monoclonal antibody, REGN7041, which was being evaluated for non‑infectious posterior uveitis.

The decision follows a safety incident observed during the trial that altered the assessment of the drug’s risk‑benefit profile. The company said the exact cause of the event has not yet been identified.

Regeneron emphasized patient safety as a priority and indicated it will continue to review the data from the study. No further details about the severity of the event or the future of REGN7041 were provided.

The halt underscores the challenges of developing immune‑targeting therapies for ocular inflammation, a field where CD3 has long been considered a potential target.